ES2191484T3 - Compuestos heterociclicos como inhibidores de enzimas de rotamasa. - Google Patents
Compuestos heterociclicos como inhibidores de enzimas de rotamasa.Info
- Publication number
- ES2191484T3 ES2191484T3 ES99963123T ES99963123T ES2191484T3 ES 2191484 T3 ES2191484 T3 ES 2191484T3 ES 99963123 T ES99963123 T ES 99963123T ES 99963123 T ES99963123 T ES 99963123T ES 2191484 T3 ES2191484 T3 ES 2191484T3
- Authority
- ES
- Spain
- Prior art keywords
- alkyl
- aryl
- independently selected
- halogen
- cycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Abstract
Un compuesto de fórmula (I): **(Fórmula)** o una sal farmacéuticamente aceptable del mismo, en el que A es un alquileno C3 - C5 no ramificado opcionalmente sustituido con un alquilo C1 - C6; X es O, S, NH o N(alquilo C1 - C6); Y es O, S, NH o N(alquilo C1 - C6); R es un grupo heterocíclico de anillo no aromático de 4 a 6 eslabones unido por un átomo de carbono, que contiene un heteroátomo de nitrógeno, estando dicho grupo opcionalmente sustituído con 1, 2, ó 3 sustituyente(s) cada uno de ellos independientemente seleccionado de alquilo C1 - C6, alquenilo C2 - C6, cicloalquilo C3 - C7, arilo, het, - CO2 (alquilo C1 - C6), - CO (het), - CONR5R6 y - CO (arilo), estando dicho alquilo y alquenilo opcionalmente sustituidos por 1 ó 2 sustituyente(s) cada uno de ellos seleccionados independientemente de cicloalquilo C3 - C7, arilo, het, - O (arilo), - O (alquileno C1 - C2)arilo, - CO (het), - CONR5R6 y - CO (arilo); R1, R2, R3 y R4 se seleccionan independientemente de H, halógeno, alquilo C1 - C6,cicloalquilo C3 - C7, haloalquilo C1 - C6), alcoxi C1 - C6, - CONR5R6, cicloalcoxi C3 - C7, cicloalquilo C3 - C7 - alquileno (C2 - C4), cicloalquilo (C3 - C7)alcoxi (C2 - C4) y - CO2(alquilo C1 - C6); R5 y R6 son, bien cada uno de ellos independientemente seleccionados entre H y alquilo C1 - C6, o bien, cuando se consideran juntos, representan un alquileno C3 - C5 no ramificado; ¿arilo¿ significa fenilo, opcionalmente sustituido con 1, 2 ó 3 sustituyente(s) cada uno de ellos independientemente seleccionado entre alquilo C1 - C6, alcoxi C1 - C6, halógeno, CONR5R6, halógeno(alquilo C1 - C6) y - NR5R6; y ¿het¿ significa un grupo heterocíclico de anillo monocíclico de 5 ó 6 eslabones, o de anillo bicíclico de 8, 9 ó 10 eslabones, que contiente de 1 a 3 heteroátomos cada uno de ellos independientemente seleccionado entre N, O y S, dicho grupo puede estar opcionalmente sustituido con 1, 2 ó 3 sustituyente(s) cada uno de ellos seleccionado independientemente entre alquilo C1 - C6, alcoxi C1 - C6,halógeno, halógeno(alquilo C1 - C6), fenilo y - NR5R6.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9815880.1A GB9815880D0 (en) | 1998-07-21 | 1998-07-21 | Heterocycles |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2191484T3 true ES2191484T3 (es) | 2003-09-01 |
Family
ID=10835920
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES99963123T Expired - Lifetime ES2191484T3 (es) | 1998-07-21 | 1999-06-28 | Compuestos heterociclicos como inhibidores de enzimas de rotamasa. |
Country Status (45)
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9815696D0 (en) * | 1998-07-20 | 1998-09-16 | Pfizer Ltd | Heterocyclics |
| GB9815880D0 (en) * | 1998-07-21 | 1998-09-16 | Pfizer Ltd | Heterocycles |
| US7781596B1 (en) | 1998-11-03 | 2010-08-24 | Abbott Laboratories | Substituted 2-phenylbenzimidazoles, the production thereof and their use |
| CO5261615A1 (es) | 1999-12-01 | 2003-03-31 | Agouron Pharma | Compuestos, composiciones y metodos para estimular el crecimiento y elongacion de neuronas |
| FR2805818B1 (fr) * | 2000-03-03 | 2002-04-26 | Aventis Pharma Sa | Derives d'azetidine, leur preparation et les compositions pharmaceutiques les contenant |
| DE10124953A1 (de) * | 2001-05-21 | 2002-12-12 | Marlies Knipper | Substanz für die therapeutische Behandlung von Tinnitus |
| JP4812758B2 (ja) * | 2004-06-29 | 2011-11-09 | アベンティス・ファーマスーティカルズ・インコーポレイテツド | Ｆｋｂｐ結合組成物及びその医薬上の使用 |
| TWI375673B (en) * | 2005-04-11 | 2012-11-01 | Abbott Lab | 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent parp inhibitors |
| US7728026B2 (en) * | 2005-04-11 | 2010-06-01 | Abbott Laboratories, Inc. | 2-substituted-1 h-benzimidazile-4-carboxamides are PARP inhibitors |
| CA2623822C (en) * | 2005-09-29 | 2013-11-12 | Abbott Laboratories | 1h-benzimidazole-4-carboxamides substituted with phenyl at the 2-position are potent parp inhibitors |
| JP5162465B2 (ja) * | 2005-11-15 | 2013-03-13 | アボット・ラボラトリーズ | 置換１ｈ−ベンズイミダゾール−４−カルボキサミド類は強力なｐａｒｐ阻害薬である |
| LT1976828T (lt) | 2005-12-29 | 2017-04-25 | Celtaxsys, Inc. | Diamino dariniai, kaip leukotrieno a4 hidrolazės inhibitoriai |
| RU2462458C2 (ru) * | 2006-02-10 | 2012-09-27 | Байомарин Ига Лимитед | Лечение миодистрофии дюшена |
| GB0602768D0 (en) * | 2006-02-10 | 2006-03-22 | Vastox Plc | Treatment of muscular dystrophy |
| SI1986633T1 (sl) * | 2006-02-10 | 2015-03-31 | Summit Corporation Plc | Zdravljenje Duchennove mišične distrofije |
| CA2647373C (en) * | 2006-05-02 | 2014-03-18 | Abbott Laboratories | Substituted 1h-benzimidazole-4-carboxamides are potent parp inhibitors |
| CA2672903C (en) | 2006-12-20 | 2012-10-23 | Amgen Inc. | Heterocyclic compounds and their use in treating inflammation, angiogenesis and cancer |
| AR065628A1 (es) * | 2007-03-07 | 2009-06-17 | Xenon Pharmaceuticals Inc | Compuestos triciclicos de utilidad en el tratamiento de trastornos por carencia de hierro en el organismo |
| US8067613B2 (en) * | 2007-07-16 | 2011-11-29 | Abbott Laboratories | Benzimidazole poly(ADP ribose)polymerase inhibitors |
| ES2617957T3 (es) * | 2007-08-03 | 2017-06-20 | Summit (Oxford) Limited | Combinaciones farmacológicas para el tratamiento de la distrofia muscular de Duchenne |
| GB0715939D0 (en) * | 2007-08-15 | 2007-09-26 | Vastox Plc | Method of treatment of duchenne muscular dystrophy |
| GB0715937D0 (en) * | 2007-08-15 | 2007-09-26 | Vastox Plc | Method of treatment og duchenne muscular dystrophy |
| DE102008060549A1 (de) | 2008-12-04 | 2010-06-10 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Wirkstoff-Peptid-Konstrukt zur extrazellulären Anreicherung |
| WO2010083199A1 (en) * | 2009-01-19 | 2010-07-22 | Abbott Laboratories | Benzthiazole inhibitors of poly(adp-ribose)polymerase |
| GB0905664D0 (en) * | 2009-04-02 | 2009-05-13 | Summit Corp Plc | Compounds for treatment of duchenne muscular dystrophy |
| EP2968359B1 (en) | 2013-03-12 | 2021-01-20 | Celltaxis, LLC | Methods of inhibiting leukotriene a4 hydrolase |
| JP6562898B2 (ja) | 2013-03-14 | 2019-08-21 | セルタクシス，インコーポレイテッド | ロイコトリエンａ４加水分解酵素の阻害剤 |
| BR112015022864A8 (pt) | 2013-03-14 | 2019-11-26 | Celtaxsys Inc | composto, composição farmacêutica e uso dos mesmos |
| KR20150127245A (ko) | 2013-03-14 | 2015-11-16 | 켈탁시스, 인코퍼레이티드 | 류코트라이엔 a4 가수분해효소의 저해제 |
| CA2949511A1 (en) * | 2014-05-19 | 2015-11-26 | Merial, Inc. | Anthelmintic compounds |
| AU2019278935A1 (en) | 2018-05-31 | 2020-12-10 | Celltaxis, Llc | Method of reducing pulmonary exacerbations in respiratory disease patients |
| CN109111376B (zh) * | 2018-09-18 | 2021-09-14 | 四川医立特生物医药有限公司 | 一种2,5-双脱氧链霉胺衍生物及其应用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5612332A (en) * | 1984-03-19 | 1997-03-18 | Alteon Inc. | Di- and triaminoguanidines, and methods of use |
| JPS6428245A (en) | 1987-07-22 | 1989-01-30 | Sumitomo Electric Industries | Production of fluoride glass |
| MX9202466A (es) | 1991-05-24 | 1994-06-30 | Vertex Pharma | Compuestos inmunosupresores novedosos. |
| CO4520280A1 (es) * | 1993-10-26 | 1997-10-15 | Boehringer Ingelheim Pharma | Derivados de pirrolidina, inhibidores de la bioscientesis de leucotrienos |
| DE19514313A1 (de) | 1994-08-03 | 1996-02-08 | Bayer Ag | Benzoxazolyl- und Benzothiazolyloxazolidinone |
| US5859031A (en) | 1995-06-07 | 1999-01-12 | Gpi Nil Holdings, Inc. | Small molecule inhibitors of rotamase enzyme activity |
| US5696135A (en) * | 1995-06-07 | 1997-12-09 | Gpi Nil Holdings, Inc. | Inhibitors of rotamase enzyme activity effective at stimulating neuronal growth |
| US5801197A (en) * | 1995-10-31 | 1998-09-01 | Gpi Nil Holdings, Inc. | Rotamase enzyme activity inhibitors |
| US5786378A (en) * | 1996-09-25 | 1998-07-28 | Gpi Nil Holdings, Inc. | Heterocyclic thioesters |
| US5801187A (en) * | 1996-09-25 | 1998-09-01 | Gpi-Nil Holdings, Inc. | Heterocyclic esters and amides |
| US5780484A (en) | 1996-11-13 | 1998-07-14 | Vertex Pharmaceuticals Incorporated | Methods for stimulating neurite growth with piperidine compounds |
| US5811434A (en) | 1996-11-13 | 1998-09-22 | Vertex Pharmacueticals Incorporated | Methods and compositions for stimulating neurite growth |
| US5840736A (en) | 1996-11-13 | 1998-11-24 | Vertex Pharmaceuticals Incorporated | Methods and compositions for stimulating neurite growth |
| US5721256A (en) | 1997-02-12 | 1998-02-24 | Gpi Nil Holdings, Inc. | Method of using neurotrophic sulfonamide compounds |
| GB9815696D0 (en) * | 1998-07-20 | 1998-09-16 | Pfizer Ltd | Heterocyclics |
| GB9815880D0 (en) * | 1998-07-21 | 1998-09-16 | Pfizer Ltd | Heterocycles |
-
1998
- 1998-07-21 GB GBGB9815880.1A patent/GB9815880D0/en not_active Ceased
-
1999
- 1999-06-28 EP EP99963123A patent/EP1100797B1/en not_active Expired - Lifetime
- 1999-06-28 IL IL14024499A patent/IL140244A0/xx unknown
- 1999-06-28 CN CNB998089974A patent/CN1174978C/zh not_active Expired - Fee Related
- 1999-06-28 CN CNA2004100399747A patent/CN1611499A/zh active Pending
- 1999-06-28 SI SI9930246T patent/SI1100797T1/xx unknown
- 1999-06-28 CN CNA2003101239079A patent/CN1511837A/zh active Pending
- 1999-06-28 WO PCT/IB1999/001211 patent/WO2000005232A1/en not_active Application Discontinuation
- 1999-06-28 DE DE69905582T patent/DE69905582T2/de not_active Expired - Fee Related
- 1999-06-28 KR KR10-2004-7007852A patent/KR100468185B1/ko not_active IP Right Cessation
- 1999-06-28 CA CA002338214A patent/CA2338214C/en not_active Expired - Fee Related
- 1999-06-28 SK SK77-2001A patent/SK772001A3/sk unknown
- 1999-06-28 ID IDW20010155A patent/ID26991A/id unknown
- 1999-06-28 KR KR10-2001-7000927A patent/KR100450008B1/ko not_active IP Right Cessation
- 1999-06-28 PL PL99345734A patent/PL345734A1/xx not_active Application Discontinuation
- 1999-06-28 HU HU0103413A patent/HUP0103413A3/hu unknown
- 1999-06-28 EE EEP200100044A patent/EE200100044A/xx unknown
- 1999-06-28 NZ NZ522270A patent/NZ522270A/en unknown
- 1999-06-28 AT AT99963123T patent/ATE233261T1/de not_active IP Right Cessation
- 1999-06-28 AU AU42858/99A patent/AU765925B2/en not_active Ceased
- 1999-06-28 GE GEAP19995715A patent/GEP20033028B/en unknown
- 1999-06-28 TR TR2001/00135T patent/TR200100135T2/xx unknown
- 1999-06-28 EA EA200100052A patent/EA003513B1/ru not_active IP Right Cessation
- 1999-06-28 BR BR9912330-4A patent/BR9912330A/pt not_active Application Discontinuation
- 1999-06-28 AP APAP/P/2001/002046A patent/AP2001002046A0/en unknown
- 1999-06-28 NZ NZ508838A patent/NZ508838A/xx unknown
- 1999-06-28 JP JP2000561188A patent/JP3795329B2/ja not_active Expired - Fee Related
- 1999-06-28 DK DK99963123T patent/DK1100797T3/da active
- 1999-06-28 OA OA1200100023A patent/OA11585A/en unknown
- 1999-06-28 ES ES99963123T patent/ES2191484T3/es not_active Expired - Lifetime
- 1999-07-07 HN HN1999000106A patent/HN1999000106A/es unknown
- 1999-07-13 TW TW088111868A patent/TWI229672B/zh not_active IP Right Cessation
- 1999-07-19 AR ARP990103544A patent/AR019427A1/es unknown
- 1999-07-19 CO CO99045677A patent/CO5080782A1/es unknown
- 1999-07-20 DZ DZ990151A patent/DZ2851A1/xx active
- 1999-07-20 GT GT199900115A patent/GT199900115A/es unknown
- 1999-07-20 MY MYPI99003048A patent/MY118222A/en unknown
- 1999-07-20 CR CR6073A patent/CR6073A/es not_active Application Discontinuation
- 1999-07-20 SV SV1999000102A patent/SV1999000102A/es not_active Application Discontinuation
- 1999-07-20 PE PE1999000727A patent/PE20001037A1/es not_active Application Discontinuation
- 1999-07-20 MA MA25691A patent/MA24936A1/fr unknown
- 1999-07-20 TN TNTNSN99147A patent/TNSN99147A1/fr unknown
- 1999-07-20 PA PA19998478501A patent/PA8478501A1/es unknown
- 1999-07-21 US US09/358,107 patent/US6372736B1/en not_active Expired - Fee Related
-
2000
- 2000-12-22 IS IS5790A patent/IS5790A/is unknown
-
2001
- 2001-01-19 HR HR20010052A patent/HRP20010052A2/hr not_active Application Discontinuation
- 2001-01-19 NO NO20010322A patent/NO20010322L/no not_active Application Discontinuation
- 2001-02-14 BG BG105254A patent/BG105254A/xx unknown
-
2002
- 2002-01-23 US US10/056,901 patent/US6562964B1/en not_active Expired - Fee Related
- 2002-02-06 HK HK02100933.8A patent/HK1039779A1/zh unknown
-
2003
- 2003-04-09 JP JP2003105099A patent/JP2004002374A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2191484T3 (es) | Compuestos heterociclicos como inhibidores de enzimas de rotamasa. | |
| AR055592A1 (es) | Derivados de 2-amino-5-cicloalquil-hidantoina como moduladores y/o inhibidores de la beta-secretasa(bace) | |
| DK0606024T3 (da) | Erythromycinderivater, en fremgangsmåde til deres fremstilling samt deres anvendelse som lægemidler | |
| RS52397B (en) | PYRIDO / 2,1-A / ISOCHINOLINE DERIVATIVES AS DPP-IV INHIBITORS | |
| AR035548A1 (es) | Compuestos organicos | |
| AR056536A1 (es) | Compuestos de 2-amino-5- [4-(difluormetoxi)fenil]-5-fenilimidazolona como inhibidores de la beta secretasa (bace) | |
| CO5721002A2 (es) | Derivados de acido 3-(4-benciloxifenil) propanoico | |
| AR055878A1 (es) | Derivados de ciclopropanocarboxamida | |
| ES2196772T3 (es) | Compuestos amino ciclicos. | |
| CO5640140A2 (es) | Inhibidores de actividad de akt | |
| AR055144A1 (es) | Inhibidor de secrecion acida | |
| AR040031A1 (es) | Compuestos de pirazol-pirimidina anilina utiles como inhibidores de cinasa y composiciones farmaceuticas que los contienen | |
| CO5160347A1 (es) | Derivados de acido carbamico | |
| AR006720A1 (es) | Un compuesto derivado de azahexano heterociclico, su uso para la preparacion de una composicion farmaceutica, procedimiento para prepararlo y una composicion farmaceutica que lo comprende | |
| EA200100487A1 (ru) | Производные 2-аминотиазола, способ их получения и применение указанных веществ в качестве противоопухолевых средств | |
| EA200100755A1 (ru) | 4-оксо-1,4-дигидро-3-хинолинкарбоксамиды как антивирусные агенты | |
| WO2007149448A3 (en) | Pyrazinones as cellular proliferation inhibitors | |
| AR117916A1 (es) | Compuesto heterocíclico y su uso | |
| AR031597A1 (es) | Compuestos piperidinos,un proceso para su preparacion, composiciones farmaceuticas,y el uso de dichos compuestos para la fabricacion de un medicamento para uso como inhibidores ccr-3 | |
| HUP0101793A2 (hu) | Antranilsav-származékok, mint cGMP-foszfodiészteráz gátlók | |
| CO6331462A2 (es) | Compuesto de fenil pirrol o una sal farmaceuticamente aceptable del mismo con actividad activadora de la glucoquinasa | |
| ECSP066415A (es) | 2-carbonilamino-6-piperidinaminopiridinas sustituidas y 1-carbonilamino-3-piperidinaminobenzenos sustituidos como 5-ht1f agonistas | |
| CO4990932A1 (es) | Derivados de 2,1,3-benzotiadiazol y proceso para su preparacion | |
| MA29559B1 (fr) | Derives de 4,5-diarylpyrrole, leur preparation et leur application en therapeutique | |
| CO4900047A1 (es) | Amidas del acido 4-(n -benzoilamino)-penten-2-enoico que tienen actividad como antagonistas de neuroquinina |